NATCO Launches First Generic Version of Revlimid® in the U.S. market

NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816), along with its marketing partner Arrow International Ltd (an affiliate of Teva Pharmaceutical Industries Ltd), have announced the launch of first generic version of Revlimid® (Lenalidomide capsules) in 5mg, 100mg, 15mg, and 25mg strengths in the U.S. market.

The above strengths of lenalidomide capsules are prescribed in adults for the treatment of (1) multiple myeloma in combination with the medicine dexamethasone, (2) certain myelodysplastic syndromes, and (3) mantle cell lymphoma following specific prior treatment. For more information refer to the prescribing information or other medical resources.

NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene (now part of Bristol-Myers Squibb).

Shares of Natco Pharma Limited was last trading in BSE at Rs. 844.30 as compared to the previous close of Rs. 870.20. The total number of shares traded during the day was 21890 in over 1602 trades.

The stock hit an intraday high of Rs. 854.00 and intraday low of 822.85. The net turnover during the day was Rs. 18335952.00.

Source : Equity Bulls

Keywords

NatcoPharma INE987B01026 ArrowInternational Teva GenericVersion Revlimid LenalidomideCapsules